Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients With Recurrent Sensitive Small Cell Lung Carcinoma

NCT00435578 is registered in ClinicalTrials.gov with Threshold Pharmaceuticals as lead sponsor.

NCT NCT00435578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00435578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients With Recurrent Sensitive Small Cell Lung Carcinoma
Lead sponsor
Threshold Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2007
Completion date
November 30, 2007
Enrollment
50 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, small cell lung